Cancer Treatment and Research Communications (Jan 2021)

Safety and efficacy of trastuzumab emtansine (TDM-1) in a patient on hemodialysis for renal failure

  • A. Falcón González,
  • P. Estévez Garcia,
  • A. Sánchez Gastaldo,
  • I. Sánchez Simón,
  • J. Salvador Boffil,
  • M. Ruiz Borrego

Journal volume & issue
Vol. 27
p. 100314

Abstract

Read online

HER2-positive metastatic breast cancer is an aggressive disease with a limited number of treatment options. In the last 15 years, new drugs such as trastuzumab, pertuzumab, lapatinib or trastuzumab emtansine (TDM-1) have sprouted for these patients. There is a huge lack of evidence on the use of some of these drugs in patients with chronic renal failure, who need hemodialysis. We have reviewed the use of TDM-1 in these type of patients in the literature with unsuccessful results.In this article we want to present a case report to illustrate the safety and efficacy of TDM-1 in a patient on hemodialysis.

Keywords